8-K: Immunic Reports Q3 2025 Results, Highlights MS Drug Potential

Immunic, Inc. announced its third-quarter 2025 financial results and provided a corporate update, emphasizing positive clinical data for vidofludimus calcium in multiple sclerosis.

Summary

• Reported financial results for the three and nine months ended September 30, 2025, alongside a corporate update.
• Key data highlighting vidofludimus calcium's therapeutic potential in Multiple Sclerosis (MS) was presented at the 41st Congress of ECTRIMS.
• Phase 2 CALLIPER data demonstrated statistically significant 24-week confirmed disability improvement in progressive MS, with consistent signals across subgroups and endpoints.
• Long-term Phase 2 EMPhASIS data in relapsing-remitting MS showed high rates of patients remaining free of confirmed disability worsening and favorable long-term safety and tolerability for up to 5.5 years.
• Top-line data from the twin Phase 3 ENSURE trials of vidofludimus calcium in relapsing MS is expected by year-end 2026.
• Received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent covering dose strengths of vidofludimus calcium for the treatment of progressive MS, expected to provide protection into 2041.
• Net loss for the three months ended September 30, 2025, was approximately $25.6 million, or $0.13 per basic and diluted share, compared to $24.4 million, or $0.24 per share, for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was approximately $77.9 million, or $0.55 per basic and diluted share, compared to $75.3 million, or $0.75 per share, for the same period in 2024.
• Cash and cash equivalents as of September 30, 2025, were $35.1 million, which is not adequate to fund operations for at least 12 months without raising additional capital.

Sentiment

Score: 6

Explanation: While clinical data for vidofludimus calcium is highly positive and de-risks future development, the significant financial challenges, particularly the inadequate cash runway and increasing net losses, temper the overall sentiment. The patent allowance is also a strong positive.

Positives

• Phase 2 CALLIPER data in progressive MS showed statistically significant 24-week confirmed disability improvement in the overall patient population, with consistent effects across PPMS and naSPMS subgroups.
• CALLIPER data supports vidofludimus calcium's neuroprotective potential and Nurr1 activation mechanism, de-risking a potential Phase 3 program for progressive MS.
• Long-term Phase 2 EMPhASIS data in relapsing-remitting MS demonstrated robust efficacy signals and a favorable safety and tolerability profile over treatment durations of up to 5.5 years.
• Received a Notice of Allowance from the USPTO for a key patent covering dose strengths of vidofludimus calcium for progressive MS, providing potential exclusivity protection into 2041 with options for further term extension.
• Vidofludimus calcium's unique profile combines neuroprotective effects (Nurr1 activation) with anti-inflammatory and anti-viral effects (DHODH inhibition), addressing the full spectrum of MS.

Negatives

• Net loss for the three months ended September 30, 2025, increased to $25.6 million from $24.4 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $77.9 million from $75.3 million in the prior year period.
• Cash and cash equivalents of $35.1 million as of September 30, 2025, are not adequate to fund operations for at least 12 months without raising additional capital.
• Interest income decreased by $0.4 million in Q3 2025 and $2.1 million in 9M 2025 primarily due to a lower average cash balance.
• Other income decreased by $0.6 million in Q3 2025, primarily due to a decrease in research and development tax incentives for clinical trials in Australia.

Risks

• Inability to raise sufficient capital to continue as a going concern and meet business objectives and operational requirements.
• Results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results.
• Risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations.
• Impact of competitive products and technological changes on product candidates.
• Risks related to the drug development and regulatory approval process.
• Increasing inflation, tariffs, and macroeconomic trends.
• Impacts of global conflicts (Ukraine-Russia, Middle East) on planned and ongoing clinical trials.
• Any changes to the size of the target markets for product candidates.
• The protection and market exclusivity provided by intellectual property.

Future Outlook

Top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials in Relapsing Multiple Sclerosis (RMS) is expected by the end of 2026. The company is preparing for further clinical testing of IMU-856, contingent on securing additional financing, licensing, or partnering. Management believes the positive Phase 2 CALLIPER data supports advancing vidofludimus calcium into Phase 3 development for progressive forms of MS.

Management Comments

• "The third quarter was marked by our strong presence at the 41st Congress of ECTRIMS, during which we had the opportunity to highlight the clinical momentum of our lead asset, vidofludimus calcium (IMU-838), an orally available nuclear receptor-related 1 (Nurr1) activator, and its potential to transform the oral multiple sclerosis (MS) therapy landscape."
• "The collective data meanwhile available from across our clinical MS trials, including the phase 2 CALLIPER and EMPhASIS trials, highlight vidofludimus calcium's unique promise to slow disability progression in both relapsing and progressive forms of the disease."
• "We believe the CALLIPER data clearly support advancing vidofludimus calcium into phase 3 development in progressive forms of MS. With only one approved therapy currently available for PPMS, there is a significant opportunity in this underserved, multi-billion-dollar market."
• "By slowing disease progression, vidofludimus calcium could help patients maintain independence, manage symptoms more effectively, and achieve improved long-term outcomes."
• "Given vidofludimus calcium's unique profile and its potential to become the oral therapy of choice addressing the full spectrum of MS, we look forward to reporting top-line data by the end of 2026."

Industry Context

The company's focus on vidofludimus calcium for progressive multiple sclerosis (PMS) positions it in a high-need, multi-billion-dollar market segment, as there is currently only one approved therapy for primary progressive MS (PPMS). This highlights a significant unmet medical need that vidofludimus calcium, with its neuroprotective and anti-inflammatory mechanisms, aims to address. The development of an oral therapy for the full spectrum of MS could offer a competitive advantage in a market dominated by various injectable and oral treatments, potentially transforming the treatment landscape.

Comparison to Industry Standards

• The company notes that "only one approved therapy currently available for PPMS," indicating a significant market opportunity for vidofludimus calcium to address an underserved patient population compared to existing treatments.

Stakeholder Impact

• Shareholders face potential for significant value creation if vidofludimus calcium succeeds in Phase 3 and commercialization, especially in the underserved progressive MS market. However, there is a risk of dilution due to the stated need for future capital raises.
• Patients with Multiple Sclerosis, particularly those with progressive forms, may benefit from a new, effective oral therapy if vidofludimus calcium progresses successfully through clinical development.
• Employees may experience continued job stability due to ongoing clinical programs, but the company's financial constraints could pose risks if additional capital is not secured.
• Creditors and investors should note the company's inadequate cash runway, indicating a high likelihood of future financing rounds and associated financial risks.

Next Steps

• Report top-line data from the twin Phase 3 ENSURE-1 and ENSURE-2 trials in Relapsing Multiple Sclerosis (RMS) by the end of 2026.
• Prepare for further clinical testing of IMU-856, contingent on securing financing, licensing, or partnering.
• Advance vidofludimus calcium into Phase 3 development in progressive forms of MS, supported by Phase 2 CALLIPER data.

Key Dates

Recommendation

The clinical data for vidofludimus calcium, particularly the statistically significant disability improvement in progressive MS and favorable long-term safety in relapsing MS, is very promising and de-risks future development. The new patent also strengthens the company's intellectual property. However, the company's financial position, marked by increasing net losses and an inadequate cash runway requiring additional capital within 12 months, presents a significant near-term challenge and risk of dilution. Investors should hold, awaiting clarity on financing and further Phase 3 results, balancing the strong clinical potential against the immediate financial hurdles.

Keywords

Multiple Sclerosis, Vidofludimus Calcium, IMU-838, Progressive MS, Relapsing MS, Nurr1 activator, DHODH inhibitor, Biotechnology, Clinical trials, Phase 2, Phase 3, ECTRIMS, Patent, Financial results, Q3 2025, Immunic, IMUX, Drug development, Neuroprotective, Anti-inflammatory, IMU-856, Gastrointestinal diseases